In this group of patients, median survival time ranges between 16–24 months and is influenced by prognostic factors like number and site of metastatic lesions as well as tumor characteristics such as hormonal receptor status and human epidermal growth factor 2-receptor (HER2) over-expression [4]. The gene discussed is ERBB2; the disease is neoplasm.